Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (494)	4/19/1999 5:51:00 PM
From: Dr. John M. de Castro	Respond to of 1494

I concur with all that has been said here on the subject. This is the best possible deal for all involved. After having watched company after company sell their shareholders out with extremely dilutive deals or deals that encourage short selling, I am gratified to see NTII protecting shareholder interests. If Jeffrey is right, and my contacts with Paul indicate that he is, then the total dillution is only 2.2 million shares outright and .44 million when the warrants are exercised. The $6 million figure that Jeffrey refers to is the target because NASDAQ requires $5 million in tangible assets for relisting. So, if NTII can land a partnership with at least $5 million in up-front money, relisting should be easy as the stock value will, I'm sure, be way north of the $1 minimum bid required. Although the spread is horrible, 11/16 is still, IMHO, dirt cheap for a stock in a company with all that NTII has going for it. The news flow over the rest of of this year should be significant and if positive, and I believe that it will be, 11/16 will look like grand theft. John de C